Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Pancreatic Neuroendocrine Tumor: early-phase trial registry
4 of 8 indexed Pancreatic Neuroendocrine Tumor trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Pancreatic Neuroendocrine Tumor: 8 US clinical trials tracked, 4 recruiting.
Pancreatic Neuroendocrine Tumor is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Aadi Bioscience, running 1 of these trials.
Enrollment posture brief
Registry condition pancreatic-neuroendocrine-tumor
OPEN 4 | RECR 50% | LATE 0 | EARLY 8 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Pancreatic Neuroendocrine Tumor lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Pancreatic Neuroendocrine Tumor on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Pancreatic Neuroendocrine Tumor is recruiting above its size-band peers.
4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Pancreatic Neuroendocrine Tumor trials is spread across many organizations.
Aadi Bioscience accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Pancreatic Neuroendocrine Tumor trials plan to enrol fewer than 100 people.
Median target enrolment is 83 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Pancreatic Neuroendocrine Tumor research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Merck Sharp & Dohme
NCT04924075
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
SWOG Cancer Research Network
NCT05040360
Multicenter Trial of ESK981 in Patients With Select Solid Tumors
University of Michigan Rogel Cancer Center
NCT05988918
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Aadi Bioscience
NCT05997056
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
NCT03074513
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
NCT03891784
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02159989
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Dana-Farber Cancer Institute
NCT01024387
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Pancreatic Neuroendocrine Tumor records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Pancreatic Neuroendocrine Tumor trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Pancreatic Neuroendocrine Tumor page
8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Pancreatic Neuroendocrine Tumor trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aadi Bioscience sponsors the most Pancreatic Neuroendocrine Tumor trials on record, review their full trial history before evaluating a specific study. See Aadi Bioscience's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pancreatic Neuroendocrine Tumor condition card totals 8 registered trials; most-linked intervention AMG 479; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.